NCT04198766 2025-12-18Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Inhibrx Biosciences, IncPhase 1/2 Active not recruiting296 enrolled
NCT05107674 2025-09-09A Study of NX-1607 in Adults With Advanced MalignanciesNurix Therapeutics, Inc.Phase 1 Recruiting345 enrolled
NCT05704985 2025-05-29Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ TumorsDEKA BiosciencesPhase 1 Active not recruiting39 enrolled
NCT03693612 2024-08-28GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsGlaxoSmithKlinePhase 1/2 Completed26 enrolled 47 charts
NCT02051751 2020-12-08A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck CancerNovartisPhase 1 Completed19 enrolled
NCT00603941 2020-09-16A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With PaclitaxelDaiichi SankyoPhase 1/2 Terminated19 enrolled 13 charts
NCT00581971 2013-04-25RAD0201University of Alabama at BirminghamPhase 1/2 Completed30 enrolled 8 charts